MCID: SRC027
MIFTS: 58

Sarcoma, Synovial

Categories: Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Sarcoma, Synovial

MalaCards integrated aliases for Sarcoma, Synovial:

Name: Sarcoma, Synovial 56 13 43 39
Synovial Sarcoma 12 74 52 58 36 29 15 17 71
Synovialosarcoma 52 58
Synovial Cell Sarcoma 52
Sarcoma Synovial 54

Characteristics:

Orphanet epidemiological data:

58
synovial sarcoma
Inheritance: Not applicable; Age of onset: All ages;

HPO:

31
sarcoma, synovial:
Inheritance somatic mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:5485
OMIM 56 300813
KEGG 36 H00050
MeSH 43 D013584
NCIt 49 C3400
SNOMED-CT 67 302851001 63211008
ICD10 via Orphanet 33 C49.9
UMLS via Orphanet 72 C0039101
Orphanet 58 ORPHA3273
MedGen 41 C0039101
SNOMED-CT via HPO 68 124975008
UMLS 71 C0039101

Summaries for Sarcoma, Synovial

KEGG : 36 Synovial sarcomas account for 7% to 10% of all human soft-tissue sarcomas. The tumors arise at any age, but affect mainly young adults and more commonly males. Clinically, they appear as deep-seated slowly growing masses. In more than half of the cases, metastases develop, primarily to the lungs but also to the lymph nodes and bone marrow. A specific translocation, t(X; 18)(p11.2; q11.2), is found in more than 90% of reported synovial sarcoma, including biphasic, monophasic, and poorly differentiated tumors. The breakpoints of the t(X; 18) have been cloned and shown to involve the fusion of the SYT gene at 18q11 to either of two highly homologous genes at Xp11 called SSX1 and SSX2. The SYT-SSX1 fusion is associated with biphasic morphology and a worse prognosis, whereas the SYT-SSX2 fusion tends to show monophasic morphology and better outcome.

MalaCards based summary : Sarcoma, Synovial, also known as synovial sarcoma, is related to spindle cell synovial sarcoma and epithelioid cell synovial sarcoma. An important gene associated with Sarcoma, Synovial is SSX2 (SSX Family Member 2), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Endometrial cancer. The drugs Lenograstim and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and t cells, and related phenotypes are synovial sarcoma and embryo

Disease Ontology : 12 A synovium cancer which develops in the synovial membrane of the joints.

NIH Rare Diseases : 52 Synovial sarcoma is a rare and aggressive soft tissue sarcoma . In the early stages of the condition, it may cause no noticeable signs or symptoms. However, as the tumor grows larger, affected people may notice a lump or swelling. In some cases, the tumor can limit range of motion or cause numbness and/or pain if it presses on nearby nerves. Although synovial sarcoma does not have a clearly defined cause, genetic factors are believed to influence the development of this disease. Cells in these tumors are usually characterized by the presence of a translocation involving chromosomes X and 18 . This translocation is specific to synovial sarcoma and is often used to diagnose the condition. Treatment generally includes a combination of surgery, radiation therapy and/or chemotherapy .

OMIM : 56 Synovial sarcomas, which represent approximately 10% of all soft tissue sarcomas, are aggressive spindle cell sarcomas containing in some cases areas of epithelial differentiation. They consistently show a specific t(X;18)(p11.2;q11.2), which usually represents either of 2 gene fusions, SYT (600192)-SSX1 (312820) or SYT-SSX2 (300192), encoding putative transcriptional proteins differing at 13 amino acid positions (summary by Ladanyi et al., 2002). Synovial sarcoma, according to the experience of Enzinger and Weiss (1983), is the fourth most common type of soft tissue sarcoma. It usually develops in adolescents and young adults, is more common in males than in females, and has no racial predilection. (300813)

Wikipedia : 74 A synovial sarcoma (also known as: malignant synovioma) is a rare form of cancer which occurs primarily... more...

Related Diseases for Sarcoma, Synovial

Diseases related to Sarcoma, Synovial via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 525)
# Related Disease Score Top Affiliating Genes
1 spindle cell synovial sarcoma 33.3 SSX2 SSX1 SS18
2 epithelioid cell synovial sarcoma 33.3 SSX2 SSX1
3 spindle cell sarcoma 32.3 VIM SSX2 SSX1 SS18 MUC1 MDM2
4 sarcoma 31.9 VIM SSX4 SSX3 SSX2 SSX1 SS18
5 mesenchymal cell neoplasm 31.9 SSX2 KIT HMGA2
6 benign mesothelioma 31.8 KRT7 CALB2
7 leiomyosarcoma 31.8 VIM MUC1 MDM2 KIT HMGA2
8 hemangiopericytoma, malignant 31.7 VIM SSX2 SSX1 SS18 MUC1 MDM2
9 malignant peripheral nerve sheath tumor 31.7 VIM MUC1 MDM2 KRT7 KIT IGF1R
10 neurilemmoma 31.7 VIM MUC1 KIT CALB2
11 pneumothorax 31.7 VIM MUC1 CALB2
12 epithelioid sarcoma 31.6 VIM MUC1 KRT7 CALB2
13 lung sarcoma 31.6 SSX2 SSX1 CALB2
14 dermatofibrosarcoma protuberans 31.5 VIM MDM2 KIT HMGA2
15 mesothelioma, malignant 31.5 VIM MUC1 KRT7 KRT19 CTNNB1 CDH1
16 carcinosarcoma 31.4 VIM MUC1 KRT7 KIT CTNNB1 CDH1
17 embryonal sarcoma 31.4 VIM MDM2 KIT CTNNB1
18 chondrosarcoma, extraskeletal myxoid 31.4 SSX2 SSX1 SS18
19 neurofibroma 31.4 VIM MUC1 KIT
20 sarcomatoid renal cell carcinoma 31.3 SSX2 MUC1 KIT CDH1
21 kidney sarcoma 31.3 SSX2 SS18
22 renal cell carcinoma, nonpapillary 31.3 VIM MUC1 KRT7 KRT19 KIT IGF1R
23 fibrosarcoma 31.3 VIM SSX2 SSX1 KIT
24 cellular myxoid liposarcoma 31.2 SSX2 SS18 MDM2 CTAG1B
25 pseudosarcomatous fibromatosis 31.2 VIM SS18 CTNNB1
26 mesenchymal chondrosarcoma 31.2 VIM MUC1 KRT7
27 thymoma 31.2 MUC1 KRT7 KIT CTNNB1 CALB2
28 spindle cell carcinoma 31.2 VIM MUC1 KRT7 KRT19 CDH1
29 angiosarcoma 31.2 VIM MUC1 MDM2 KRT7 KIT FLI1
30 lipomatosis, multiple 31.2 MDM2 KIT HMGA2
31 hemangioma 31.2 MUC1 KRT7 KIT FLI1 CTNNB1
32 secretory meningioma 31.1 VIM MUC1 KRT7
33 sarcomatoid mesothelioma 31.1 VIM MUC1 CALB2
34 rhabdoid tumor predisposition syndrome 1 31.1 VIM MUC1 IGF1R
35 myxoid liposarcoma 31.1 SSX2 SSX1 SS18 MDM2 KRT19 IGF1R
36 adenoma 31.1 MUC1 KRT7 CTNNB1 CDH1
37 chondroma 31.1 KIT HMGA2 CTNNB1
38 biphasic synovial sarcoma 31.1 VIM SSX4 SSX2 SSX1 SS18 MUC1
39 angiomyolipoma 31.1 VIM KRT7 KIT
40 pleomorphic lipoma 31.1 MDM2 HMGA2
41 small cell carcinoma 31.1 MUC1 KRT7 KRT19 KIT
42 malignant fibrous histiocytoma 31.1 VIM MUC1 MDM2 KIT
43 dedifferentiated liposarcoma 31.0 SSX2 SSX1 SS18 MUC1 MDM2 KIT
44 liposarcoma 31.0 VIM MDM2 IGF1R HMGA2 CTNNB1 CALB2
45 papillary carcinoma 31.0 MUC1 KRT7 KRT19 CDH1 CALB2
46 adenocarcinoma 31.0 MUC1 MDM2 KRT7 KIT IGF1R CTNNB1
47 peritoneal mesothelioma 30.9 VIM MUC1 CALB2
48 endosalpingiosis 30.9 MUC1 KRT7 CALB2
49 heart sarcoma 30.9 SSX2 SSX1 MDM2 KIT
50 pericardium cancer 30.9 KRT7 KRT19 CALB2

Graphical network of the top 20 diseases related to Sarcoma, Synovial:



Diseases related to Sarcoma, Synovial

Symptoms & Phenotypes for Sarcoma, Synovial

Human phenotypes related to Sarcoma, Synovial:

31
# Description HPO Frequency HPO Source Accession
1 synovial sarcoma 31 HP:0012570

Clinical features from OMIM:

300813

MGI Mouse Phenotypes related to Sarcoma, Synovial:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.61 CDH1 CTNNB1 FLI1 IGF1R KIT KRT19
2 neoplasm MP:0002006 9.17 CDH1 CTNNB1 FLI1 IGF1R KIT KRT19

Drugs & Therapeutics for Sarcoma, Synovial

Drugs for Sarcoma, Synovial (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 3 135968-09-1
2
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
3
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
4
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
5
Gemcitabine Approved Phase 3 95058-81-4 60750
6
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
7
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
8
Epirubicin Approved Phase 3 56420-45-2 41867
9
Ifosfamide Approved Phase 2, Phase 3 3778-73-2 3690
10
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
11
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
12
Mechlorethamine Approved, Investigational Phase 2, Phase 3 51-75-2 4033
13
Idarubicin Approved Phase 3 58957-92-9 42890
14
Etoposide Approved Phase 3 33419-42-0 36462
15
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
16
Histamine Approved, Investigational Phase 3 51-45-6 774
17
Cyproheptadine Approved Phase 3 129-03-3 2913
18 Trofosfamide Investigational Phase 3 22089-22-1
19 Antirheumatic Agents Phase 3
20 Immunologic Factors Phase 3
21 Anti-Infective Agents Phase 3
22 Antiviral Agents Phase 3
23 Tubulin Modulators Phase 3
24 Immunosuppressive Agents Phase 3
25 Antimetabolites Phase 3
26 Antimitotic Agents Phase 3
27
Isophosphamide mustard Phase 2, Phase 3 0
28 Etoposide phosphate Phase 3
29 Vaccines Phase 3
30
Liposomal doxorubicin Phase 2, Phase 3 31703
31 Anti-Bacterial Agents Phase 2, Phase 3
32 Antibiotics, Antitubercular Phase 2, Phase 3
33 Neurotransmitter Agents Phase 3
34 Histamine Antagonists Phase 3
35 Anti-Allergic Agents Phase 3
36
Histamine Phosphate Phase 3 51-74-1 65513
37 Histamine H1 Antagonists Phase 3
38 Dermatologic Agents Phase 3
39 Gastrointestinal Agents Phase 3
40
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
41
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
42
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
43
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
44
Everolimus Approved Phase 1, Phase 2 159351-69-6 70789204 6442177
45
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
46
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
47
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
48
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
49
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
50
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062

Interventional clinical trials:

(show top 50) (show all 137)
# Name Status NCT ID Phase Drugs
1 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Unknown status NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Phase III Study of The Role of Barrier Resection in Local Control in Treatment of Extremity Soft Tissue Sarcomas Unknown status NCT02120768 Phase 3
4 Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
6 A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcomas (RPS) Completed NCT00091351 Phase 3
7 Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
8 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
10 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
11 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
12 A Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma Recruiting NCT03016819 Phase 3 AL 3818;Dacarbazine
13 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
14 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Active, not recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
15 A Randomised Phase-III Trial of the Cooperative Weichteilsarkom Study Group (CWS) for Localised High-risk Rhabdomyosarcoma and Localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in Children, Adolescents, and Young Adults Active, not recruiting NCT00876031 Phase 3 trofosfamide, idarubicin, etoposide
16 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally-advanced or Metastatic NY-ESO-1+ Synovial Sarcoma Participants Following First Line Systemic Anti-cancer Therapy (V943-003, IMDZ-04-1702) Terminated NCT03520959 Phase 3
17 TRUSTS: A Phase IIB/III Multicenter Study Comparing the Efficacy of TRabectedin Administered as a 3-Hour or 24-Hour Infusion to Doxorubicin in Patients With Advanced or Metastatic Untreated Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
18 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
19 Time to Secondary Resistance to Trabectedin After Interruption Versus Continuation in Responding Patients With Liposarcoma, Leiomyosarcoma and Synovial Sarcoma Withdrawn NCT03773510 Phase 3 Trabectedin discontinuation;Trabectedin continuation
20 Activity and Safety of Regorafenib in Patients With Metastatic Soft Tissue Sarcoma Previously Treated With Anthracycline-based Chemotherapy : a Multinational, Randomized, Phase II, Placebo-controlled Trial Unknown status NCT01900743 Phase 2 Regorafenib;Placebo
21 A Clinicopathological Phase II Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas Unknown status NCT01140737 Phase 2 Axitinib
22 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
23 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
24 Phase II Study of GW786034 in Patients With Relapsed or Refractory Soft Tissue Sarcoma Completed NCT00297258 Phase 2 pazopanib
25 Phase II Study Of Iressa (ZD 1839) In Locally Advanced And/Or Metastatic Synovial Sarcoma Expressing HER1/EGFR1 Completed NCT00052754 Phase 2 gefitinib
26 Phase II Study of Trastuzumab (NSC-688097) in Treatment of Locally Advanced or Metastatic Synovial Sarcoma Completed NCT00104949 Phase 2
27 A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients With Previously-Treated, Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET Completed NCT00668148 Phase 2
28 A Phase 1b/2 Study of Imatinib in Combination With Everolimus in Synovial Sarcoma Completed NCT01281865 Phase 1, Phase 2 everolimus;imatinib mesylate
29 Phase I/II Trial of Torisel and Liposomal Doxorubicin in Patients With Advanced Soft Tissue and Bone Sarcomas Completed NCT00949325 Phase 1, Phase 2 temsirolimus plus liposomal doxorubicin
30 Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults With Refractory Solid Tumors Completed NCT00331643 Phase 2 ixabepilone
31 A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas Completed NCT00245102 Phase 2 sorafenib tosylate
32 A Phase 2 Study of Intravenous REOLYSIN® (Wild-Type Reovirus) in the Treatment of Patients With Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
33 A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1 Completed NCT02609984 Phase 2
34 A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas Completed NCT00112463 Phase 2 romidepsin
35 A Phase II Study of Gleevec (Imatinib Mesylate, NSC 716051 Formerly STI571) in Children With Refractory or Relapsed Solid Tumors Completed NCT00030667 Phase 2 imatinib mesylate
36 Phase II Trial of Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
37 A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors Completed NCT00831844 Phase 2
38 A Phase II Study of Neoadjuvant Bevacizumab and Radiation Therapy for Resectable Soft Tissue Sarcomas Completed NCT00356031 Phase 2 Bevacizumab
39 A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Completed NCT01614795 Phase 2 Temsirolimus
40 A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
41 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
42 A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas. Completed NCT00642941 Phase 2 RG1507
43 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
44 Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group Completed NCT00041236 Phase 2 exatecan mesylate
45 A Phase II Randomized - Non Comparative - Study on the Activity of Trabectedin or Gemcitabine + Docetaxel in Metastatic or Locally Relapsed Uterine Leiomyosarcoma Pretreated With Conventional Chemotherapy Completed NCT02249702 Phase 2 gemcitabine + docetaxel;trabectedin
46 Efficacy And Safety Study Of Brostallicin In Patients With Locally Advanced Or Metastatic Soft Tissue Sarcoma Failing One Prior Chemotherapy Treatment Completed NCT00041249 Phase 2 brostallicin
47 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
48 A Phase II Study of Intravenous TZT-1027, Administered Weekly Times Two, Every Three Weeks, to Patients With Advanced or Metastatic Soft Tissue Sarcomas (STS) With Prior Exposure to Anthracycline-Based Chemotherapy Completed NCT00064220 Phase 2 soblidotin
49 A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
50 Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft Tissue Sarcoma After Pre-treatment Failure: an Open-label, Multicenter Phase II Study Completed NCT01136499 Phase 2 LBH589 (Panobinostat®)

Search NIH Clinical Center for Sarcoma, Synovial

Cochrane evidence based reviews: sarcoma, synovial

Genetic Tests for Sarcoma, Synovial

Genetic tests related to Sarcoma, Synovial:

# Genetic test Affiliating Genes
1 Synovial Sarcoma 29 SSX1 SSX2

Anatomical Context for Sarcoma, Synovial

MalaCards organs/tissues related to Sarcoma, Synovial:

40
Bone, Lung, T Cells, Kidney, Lymph Node, Bone Marrow, Heart

Publications for Sarcoma, Synovial

Articles related to Sarcoma, Synovial:

(show top 50) (show all 3332)
# Title Authors PMID Year
1
The SYT-SSX1 fusion type of synovial sarcoma is associated with increased expression of cyclin A and D1. A link between t(X;18)(p11.2; q11.2) and the cell cycle machinery. 56 61
12173050 2002
2
Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. 56 61
11782370 2002
3
SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. 56 61
9428816 1998
4
Localization of X chromosome short arm markers relative to synovial sarcoma- and renal adenocarcinoma-associated translocation breakpoints. 61 56
8406438 1993
5
Localization of the synovial sarcoma t(X;18)(p11.2;q11.2) breakpoint by fluorescence in situ hybridization. 61 56
1338692 1992
6
A synovial sarcoma with t(X;18)(p11;q11) in a patient with Turner's syndrome. 56 61
1373322 1992
7
Translocation X;18 and insertion 15;11 in a case of synovial sarcoma. 56 61
2825963 1988
8
Another synovial sarcoma with t(X;18) 56 61
2822225 1987
9
Chromosomal changes in soft-tissue sarcomas. A new diagnostic parameter. 56 61
2823744 1987
10
A consistent chromosome translocation in synovial sarcoma. 56 61
3030536 1987
11
Translocation (X;18) in a synovial sarcoma. 56 61
3030537 1987
12
Involvement of chromosome X in primary cytogenetic change in human neoplasia: nonrandom translocation in synovial sarcoma. 56 61
3031659 1987
13
Cryptic SYT/SXX1 fusion gene in high-grade biphasic synovial sarcoma with unique complex rearrangement and extensive BCL2 overexpression. 61 54
20082858 2010
14
Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma. 61 54
19809272 2009
15
Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1. 54 61
19936258 2009
16
Metastatic poorly differentiated monophasic synovial sarcoma to lung with unknown primary: a molecular genetic analysis. 61 54
20126590 2009
17
Molecular and immunohistochemical analyses of BCL2, KI-67, and cyclin D1 expression in synovial sarcoma. 54 61
19602458 2009
18
Cytosolic SYT/SS18 isoforms are actin-associated proteins that function in matrix-specific adhesion. 61 54
19649286 2009
19
Human synovial sarcoma proto-oncogene Syt is essential for early embryonic development through the regulation of cell migration. 61 54
19333234 2009
20
Reactivation of p53 function in synovial sarcoma cells by inhibition of p53-HDM2 interaction. 61 54
19081178 2009
21
Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. 61 54
18855347 2008
22
Cryptic chromosome rearrangement resulting in SYT-SSX2 fusion gene in a monophasic synovial sarcoma. 54 61
18992642 2008
23
Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. 54 61
18519690 2008
24
Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth. 54 61
18267106 2008
25
The C terminus of the synovial sarcoma-associated SSX proteins interacts with the LIM homeobox protein LHX4. 61 54
17667940 2008
26
Expression of MYCN in pediatric synovial sarcoma. 61 54
17464317 2007
27
[Roles of immunohistochemistry and detection of SYT-SSX fusion gene in diagnosis of synovial sarcoma]. 54 61
17845763 2007
28
Opportunities for improving the therapeutic ratio for patients with sarcoma. 54 61
17540303 2007
29
Immunostaining for SYT protein discriminates synovial sarcoma from other soft tissue tumors: analysis of 146 cases. 54 61
17334346 2007
30
Modeling synovial sarcoma: timing is everything. 54 61
17418406 2007
31
The SYT-SSX fusion protein down-regulates the cell proliferation regulator COM1 in t(x;18) synovial sarcoma. 61 54
17101797 2007
32
The (epi)genetics of human synovial sarcoma. 61 54
17117414 2007
33
Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma: special reference to its inverse relationship with E-cadherin expression. 61 54
17197923 2007
34
Primary synovial sarcoma in fallopian tube: case report and literature review. 61 54
17197895 2007
35
Expression of claudin7 is tightly associated with epithelial structures in synovial sarcomas and regulated by an Ets family transcription factor, ELF3. 54 61
17060315 2006
36
The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation. 61 54
17018603 2006
37
Biphasic synovial sarcoma of the abdominal wall. 61 54
16855839 2006
38
Adaptor molecule Crk is required for sustained phosphorylation of Grb2-associated binder 1 and hepatocyte growth factor-induced cell motility of human synovial sarcoma cell lines. 61 54
16849525 2006
39
SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: a potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma. 61 54
16849535 2006
40
The synovial sarcoma translocation protein SYT-SSX2 recruits beta-catenin to the nucleus and associates with it in an active complex. 54 61
16462762 2006
41
Beta-catenin nuclear expression correlates with cyclin D1 expression in primary and metastatic synovial sarcoma: a tissue microarray study. 61 54
16740029 2006
42
Extent, relationship and prognostic significance of apoptosis and cell proliferation in synovial sarcoma. 54 61
16679870 2006
43
Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma. 54 61
16528378 2006
44
A variant of the SYT-SSX2 fusion gene in a case of synovial sarcoma. 54 61
16682293 2006
45
Synovial sarcoma with radiological appearances of primitive neuroectodermal tumour/Ewing sarcoma: differentiation by molecular genetic studies. 61 54
16220269 2006
46
G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line. 61 54
16450387 2006
47
Molecular alterations of monophasic synovial sarcoma: loss of chromosome 3p does not alter RASSF1 and MLH1 transcriptional activity. 61 54
16329043 2006
48
IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. 54 61
16247461 2006
49
Synovial sarcoma of the mandible. 54 61
16393257 2006
50
Common origin of the human synovial sarcoma associated SS18 and SS18L1 gene loci. 54 61
16484776 2006

Variations for Sarcoma, Synovial

Cosmic variations for Sarcoma, Synovial:

9 (show top 50) (show all 155)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM150913721 CTNNB1 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
2 COSM151345135 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.74A>T p.D25V 3:41224607-41224607 16
3 COSM149585128 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
4 COSM150526369 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
5 COSM109692021 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
6 COSM151979842 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
7 COSM151558671 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
8 COSM150452603 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
9 COSM110179560 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
10 COSM151812183 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
11 COSM151326078 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.74A>T p.D25V 3:41224607-41224607 16
12 COSM150961248 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.74A>T p.D25V 3:41224607-41224607 16
13 COSM89368484 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
14 COSM150733816 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.74A>T p.D25V 3:41224607-41224607 16
15 COSM102378542 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
16 COSM150088852 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.74A>T p.D25V 3:41224607-41224607 16
17 COSM149957835 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.74A>T p.D25V 3:41224607-41224607 16
18 COSM151491624 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.74A>T p.D25V 3:41224607-41224607 16
19 COSM151343626 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.74A>T p.D25V 3:41224607-41224607 16
20 COSM111887159 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
21 COSM151748866 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
22 COSM150659626 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
23 COSM149384200 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
24 COSM149480779 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
25 COSM111036451 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
26 COSM146867874 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
27 COSM151307809 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
28 COSM111893799 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.74A>T p.D25V 3:41224607-41224607 16
29 COSM105888206 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
30 COSM150275123 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
31 COSM150868112 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.74A>T p.D25V 3:41224607-41224607 16
32 COSM150310035 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
33 COSM102450835 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
34 COSM146243416 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
35 COSM151827154 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
36 COSM151591559 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
37 COSM150142211 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
38 COSM150814289 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.95A>T p.D32V 3:41224607-41224607 16
39 COSM149290749 soft tissue,fibrous tissue and uncertain origin,synovial sarcoma,biphasic c.74A>T p.D25V 3:41224607-41224607 16
40 COSM87902864 TP53 soft tissue,upper leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 12
41 COSM87935416 TP53 soft tissue,upper leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 12
42 COSM93992510 SRC soft tissue,lung,sarcoma,NS c.205T>G p.S69A 20:37384358-37384358 12
43 COSM92479334 SH2B3 soft tissue,upper leg,sarcoma,NS c.232G>A p.E78K 12:111418377-111418377 12
44 COSM93451505 RAC1 soft tissue,lung,sarcoma,NS c.533C>T p.A178V 7:6402343-6402343 12
45 COSM101931022 PTPRD soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 12
46 COSM90842465 PTCH1 soft tissue,lung,sarcoma,NS c.2921T>G p.F974C 9:95458260-95458260 12
47 COSM87210160 PIK3CA soft tissue,lung,sarcoma,NS c.1036G>T p.V346L 3:179203766-179203766 12
48 COSM101270110 PBRM1 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 12
49 COSM98770048 PAK5 soft tissue,lung,sarcoma,NS c.41C>A p.P14Q 20:9644288-9644288 12
50 COSM88525472 NUP93 soft tissue,upper leg,sarcoma,NS c.116C>T p.A39V 16:56748363-56748363 12

Copy number variations for Sarcoma, Synovial from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 120197 18 21850214 21924609 Translate SS18 Synovial sarcoma

Expression for Sarcoma, Synovial

Search GEO for disease gene expression data for Sarcoma, Synovial.

Pathways for Sarcoma, Synovial

Pathways related to Sarcoma, Synovial according to KEGG:

36
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

GO Terms for Sarcoma, Synovial

Cellular components related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.8 VIM SSX4 SSX3 SSX2 SSX1 SS18
2 flotillin complex GO:0016600 8.62 CTNNB1 CDH1

Biological processes related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.65 VIM MDM2 KIT HMGA2 CTNNB1
2 entry of bacterium into host cell GO:0035635 9.16 CTNNB1 CDH1
3 positive regulation of transcription, DNA-templated GO:0045893 9.1 SS18 HMGA2 FLI1 ELF3 CTNNB1 CDH1
4 cellular response to indole-3-methanol GO:0071681 8.96 CTNNB1 CDH1

Molecular functions related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.58 VIM SSX3 SSX2 SSX1 SS18 MUC1

Sources for Sarcoma, Synovial

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....